Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- FDA Clears Shionogi’s COVID-19 Pill for Global PIII Study
March 17, 2022
- Aduhelm Deal Revised, Eisai Poised to Sharpen Focus on Lecanemab: CEO
March 17, 2022
- Biogen/Eisai Alzheimer’s Pact Amended to Switch Aducanumab Collab to Royalty Scheme
March 16, 2022
- Astellas’ Vasomotor Symptom Med Missed Primary Goal in Asian PIII Study
March 16, 2022
- AbbVie Seeks Japan Approval of Advanced Parkinson’s Med, New Indication for Rinvoq
March 15, 2022
- Mitsubishi Tanabe’s Oral Edaravone Filed in Japan for ALS
March 15, 2022
- ViiV Submits Long-Acting Cabotegravir Injectable for HIV in Japan
March 14, 2022
- Nubeqa Filed for Metastatic Prostate Cancer in Japan: Bayer
March 14, 2022
- Moderna Accelerating Bivalent Vaccine Development for 4th COVID Shot: Japan Chief
March 14, 2022
- Fujifilm Drops Avigan’s Japan PIII Trial for COVID-19
March 14, 2022
- Shionogi, XNef, ATR Join Hands on R&D for Diagnosis/Stratified Markers of Neuropsychiatric Disorders
March 14, 2022
- Sumitomo Dainippon Invests an Additional 200 Million Yen into Aikomi
March 14, 2022
- Toho Gets 20% Stake in Ayumi’s Holdings Firm, Eyes RA Biosimilar Market
March 11, 2022
- Authorized Generics Likely Speeding Up G1/G2 Price Cuts for Off-Patent Brands: Jiho Tally
March 11, 2022
- Chugai Won’t Challenge Edirol Substance Patent Ruling
March 11, 2022
- Toa Eiyo Kickstarts Japan PIIb/III for Sakigake Designated TGCV Med
March 11, 2022
- Japan Drug Makers Moving to Support War-Hit Ukraine
March 10, 2022
- Opdivo Tops Japan Sales Ranking in February: Encise
March 10, 2022
- Astellas to Submit Improvement Plans for Gene Therapy Trial by September over Patient Deaths
March 10, 2022
- Double-Digit Slashes to Hit 44 Major Drugs in 2022 Price Revision: Top 5 Product Poll
March 9, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…